Expression of MDR proteins in breast cancer and its correlation with some clinical and pathological parameters

Neoplasma

Volumn 53, Issue 2, 2006, Pages 128-135

  Rybarova S ^a   Hodorova I ^a   Hajdukova M ^a   Schmidtova K ^a   Mojzis J ^a   Kajo, K ^b   Kviatkovska Z ^b   Plank, L ^b   Benicky M ^a   Mirossay A ^a   Biros E ^a   Bobrov, N ^a   Wagnerova M ^c   Berc A ^c   Mirossay, L ^a  

^a P J AFÁRIK UNIVERSITY   (Slovakia)

^b University Teaching Hospital in Martin   (Slovakia)

^c Vychodoslovensky Onkologicky Ustav Kosice   (Slovakia)

Author keywords

Breast cancer; Immunohistochemistry; LRP protein; MDR1 protein; MRP1 protein

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CANCER; CANCER GRADING; CELL NUCLEUS MEMBRANE; CONTROLLED STUDY; CYTOPLASM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RANK SUM TEST;

EID: 33645469844     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. HOFFMANN J, SOMMER A. Steroid hormone receptors as targets for the therapy of breast and prostate cancer-recent advances, mechanisms of resistance, and new approaches. J Steroid Biochem Mol Biol 2005; 93: 191-200.
2. LARKIN A, O'DRISCOLL L, KENNEDY S, PURCELL R, MORAN E et al. Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: a prognostic study. Int J Cancer 2004; 112: 286-294.
3. LOHRISCH C, PICCART M. An overview of HER2. Semin Oncol 2001; 8 Suppl 18: 3-11.
4. NICHOLSON S, SAINSBURY JR, HALCROW P, CHAMBERS P, FARNDON JR et al. Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet 1989; 1: 182-185.
5. LAGE H. Drug resistance in breast cancer. Cancer Therapy 2003; 1: 81-91.
6. EARP HS, DAWSON TL, LI X, YU H. Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat 1995; 35: 115-132.
7. COLLINS LC, SCHNITT SJ. HER2 protein overexpression in estrogen receptor-positive ductal carcinoma in situ of the breast: frequency and implications for tamoxifen therapy. Mod Pathol 2005; (Epub ahead of print)
8. GUARNERI V, BENGALA C, ORLANDINI C, GENNARI A, DONATI S et al. HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support. Bone Marrow Transplant 2004; 34: 413-417.
9. DE FAZIO A, CHIEW YE, SINI RL, JANES PW, SUTHERLAND RL. Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. Int J Cancer 2000; 87: 487-498.
10. PICCART M, LOHRISCH C, DI LEO A, LARSIMONT D. The predictive value of Her2 in breast cancer. Oncology 2001; 61 Suppl 2: 73-82.
11. FILIPITS M, SUCHOMEL RW, DEKAN G, HAIDER K, VALDIMARSSON G et al. MRP and MDR1 gene expression in primary breast carcinomas. Clin Cane Res 1996; 2: 1231-1237.
12. SIMON SM, SCHINDLER M. Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA 1994; 91: 3497-3504.
13. LINN SC, PINEDO HM, VAN ARK-OTTE J, VAN DER VALK P, HOEKMAN K et al. Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int J Cancer 1997; 71: 787-795.
14. NOOTER K, BRUTEL DE LA RIVIERE G, LOOK MP, VAN WINGERDEN KE et al. The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br J Cancer 1997; 76: 486-493.
15. RUDAS M, FILIPITS M, TAUCHER S, STRANZL T, STEGER GG et al. Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy. Breast Cancer Res Treat 2003; 81: 149-157.
16. SCHNEIDER J, LUCAS R, SÁNCHEZ J, RUIBAL A, TEJERINA A et al. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: Correlation with the response to therapy and the expression of MDR1 and LRP. Anticancer Res 2000; 20: 4373-4378.
17. SCHEFFER GL, MALIEPAARD M, PIJNENBORG ACLM, VAN GASTELEN MA, DE JONG MC et al. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. Cancer Res 2000; 60: 2589-2593.
18. ELSTON CW, ELLIS IO. Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: Experience from a large study with long term follow up. Histopathology 1991; 19: 403-410.
19. HSIA TC, LIN CC, WANG JJ, HO ST, KAO A. Relationship between chemotherapy response of small cell lung cancer and P-glycoprotein or multidrug resistance-related protein expression. Lung 2002; 180: 173-179.
20. LI EX, LI Y, YANG J, HE J, CHEN L et al. Influence of P-glycoprotein expression on chemotherapeutic response of metastatic breast carcinoma. Ai Zheng 2002; 21: 430-432.
21. FILIPITS M, MALAYERI R, SUCHOMEL RW, POHL G, STRANZL T et al. Expression of the multidrug resistance protein (MRP1) in breast cancer. Anticancer Res 1999; 19: 5043-5050.
22. IZQUIERDO MA, SCHEFFER GL, FLENS MJ, GIACCONE G, BROXTERMAN HJ et al. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J Pathol 1996; 148: 877-887.
23. POHL G, FILIPITS M, SUCHOMEL RW, STRANZL T, DEPISCH D et al. Expression of the lung resistance protein (LRP) in primary breast cancer. Anticancer Res 1999; 19: 5051-5055.
24. FANEYTE IF, KRISTEL PM, VAN DE VIJVER MJ. Multidrug resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer. Anticancer Res 2004; 24: 2931-2939.
25. YU P, XIAO NX, CHEN YP. Expression of P-glycoprotein and lung resistance protein in breast carcinoma and its relationship with prognosis. Ai Zheng 2003; 22: 1339-1342.
26. BURCOMBE RJ, MAKRIS A, RICHMAN PI, DALEY FM, NOBLE S et al. Evaluation of ER, PgR, Her-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer 2005; 92: 147-155.
27. LIZARD-NACOL S, GENNE P, COUDERT B, RIEDINGER JM, ARNAL M et al. MDR1 and thymidylate synthase (TS) gene expressions in advanced breast cancer: Relationship to drug exposure, p53 mutations, and clinical outcome of the patients. Anticancer Res 1999; 19: 3575-3582.
28. MORIKI T, TAKAHASHI T, TANIOKA F, YAMANE T, HARA H. Proliferative activity in breast carcinoma evaluated by BrdU and PCNA. Correlation with expression of p53, c-erbB-2, estrogen receptor and P-glycoprotein. Pathol Res Pract 1995; 191: 1122-1132.
29. HAHNEL R, SPILSBURY K. Oestrogen receptors revisited: Long-term follow up of over five thousand breast cancer patients. ANZ J Surg 2004; 74: 957-960.
30. DEXTER DW, REDDY RK, GELES KG, BANSAL S, MYINT MA et al. Quantitative reverse transcriptase-polymerase chain reaction measured expression of MDR1 and MRP in primary breast carcinoma. Clin Cancer Res 1998; 4: 1533-1542.
31. TROCK BJ, LEONESSA F, CLARKE R. Multidrug resistance in breast cancer: A meta-analysis of MDR1/gp170 expression and its possible functional significance. JNCI 1997; 89: 917-931.
32. LEONESSA F, CLARKE R. ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 2003; 10: 43-73.
33. ZAMPIERI L, BIANCHI P, RUFF P, ARBUTHNOT P. Differential modulation by estradiol of P-glycoprotein drug resistance protein expression in cultured MCF7 and T47D breast cancer cells. Anticancer Res 2002; 22: 2253-2259.
34. PIEKARZ RL, COHEN D, HORWITZ SB. Progesterone regulates the murine multidrug resistance mdr1b gene. J Biol Chem 1993; 268: 7613-7616.